Indeed, in our study, we found that the proliferation and metastasis capacities of NSCLC cells could only be partially recovered when PPIP5K2 silenced cells were treated with AKT/mTOR agonists, while the capacities of PPIP5K2 overexpressed NSCLC cells were completely restored post treatment of AKT/mTOR antagonists, suggesting that multiple signaling pathways, primarily AKT/mTOR signaling, may be involved in PPIP5K2-mediated NSCLC progression. Here, PPIP5K2 is linked to non-small cell lung carcinoma.